Abstract | In the past decade, the prevalence, significance, and regulatory mechanisms of vascular calcification have gained increasing recognition. Over a century ago, pathologists recognized atherosclerotic calcification as a form of extraskeletal ossification. Studies are now identifying the mechanism of this remarkable process as a recapitulation of embryonic endochondral and membranous ossification through phenotypic plasticity of vascular cells that function as adult mesenchymal stem cells. These embryonic developmental programs, involving bone morphogenetic proteins and potent osteochondrogenic transcription factors, are triggered and modulated by a variety of inflammatory, metabolic, and genetic disorders, particularly hyperlipidemia, chronic kidney disease, diabetes, hyperparathyroidism, and osteoporosis. They are also triggered by loss of powerful inhibitors, such as fetuin A, matrix Gla protein, and pyrophosphate, which ordinarily restrict biomineralization to skeletal bone. Teleologically, soft-tissue calcification might serve to create a wall of bone to sequester noxious foci such as chronic infections, parasites, and foreign bodies. This Review focuses on atherosclerotic and medial calcification. The capacity of the vasculature to produce mineral in culture and to produce de novo, vascularized, trabecular bone and cartilage tissue, even in patients with osteoporosis, should intrigue investigators in tissue engineering and regenerative biology.
Introduction
In 2009, a meta-analysis of 30 prospective cohort studies demonstrated the consistent finding that presence of vascular calcification poses an increased risk of cardiovascular and all-cause mortality. 1 In coronary arteries, calcified plaque independently predicts a 1.7-fold increase in mortal ity. 2 When coronary calcification is extensive, mortality is increased 60-fold. 2 Calcification of peripheral arteries also independently predicts mortal ity, as well as risk of amputation. 3 By far, the most-extensive vascular calcification occurs in patients with chronic kidney disease, 4 followed by those with type II diabetes mellitus. 5 Nevertheless, nearly all patients with cardiovascular disease have some degree of calcification, 6 and, in asymptomatic adults, prevalence of coronary calcification corresponds roughly with age; among 60-year-olds, approximately 60% have calcific vasculopathy. 1, 2 Controversy remains with respect to whether vascular calcification is a cause or consequence of cardio vascular disease. Most likely, it is both: a consequence, in that atherosclerosis induces cellular osteogenic differentiation; and a cause, in that vascular calcification stiffens the aorta and affects plaque stability. Calcium deposits might affect plaque stability by introducing compliance mismatch at the interface of the rigid mineral with the more distensible artery wall tissue. Under mechanical stress, this interface has an increased risk of mechanical failure (plaque rupture). 7 Such plaque rupture is believed to cause most myocardial infarction and stroke events. 8 Finite element analysis has demonstrated that calcium deposits dramatically redistribute stress in plaque, reducing it in some regions at the cost of increasing it in others. 7 The net effect of calcium deposition on risk of rupture depends on the anatomic orientation of the calcium deposits relative to the plaque and any necrotic core. 9, 10 Aortic rigidity-the most insidious effect of vascular calcification 11, 12 -results in hypertension, left ventricular hypertrophy, ischemia, heart failure, amputation, and death. 5 In this article, we review the regulatory mechanisms in vascular calcification. More than a century ago, investigators recognized vascular calcification as a form of extraskeletal ossification. 13, 14 This concept was forgotten in the past century, when cholesterol dominated the field; vascular calcium deposits became regarded as passive, inevitable, unregulated, and degenerative consequences of aging. In the past decade, however, the prevalence, signifi cance, and regulatory mechanisms of vascular calcifi cation have gained recognition among investi gators and clinicians. vasculopathy can also be distinguished by its histological appearance as either amorphous (lacking tissue architecture) or chondro-osseous (having the tissue architecture of cartilage or, when microvascular invasion occurs, even bone) (Figure 1 ). Amorphous calcified matrix is far more common than the chondro-osseous form, but the latter often seems to emerge from the former, which may repre sent a precursor lesion.
Neointimal calcium deposits are found in a patchy distribution throughout the vascular tree, co-localizing with atherosclerotic lesions. Calcification was pre viously thought to occur only in the most-advanced, end-stage plaques in the elderly. However, small (5-10 μm) hydroxyapatite mineral crystals arise in early lesions in the third decade of life, 15 and coronary calcium deposition is now used as a quantitative marker for athero sclerotic plaque burden, even in early, subclinical stages. 16 Medial calcium deposits are distributed more diffusely throughout the vascular tree, at sites with or without atherosclerosis, and are more often circumferential at a given site owing to the close association with elastic laminae (discussed below). Medial calcification is primarily associated with chronic kidney disease and diabetes. In microvessels, medial calcification is known as calcific uremic arteriolopathy, previously calciphylaxis.
Cardiac valve leaflets, although anatomically distinct from vessels, also undergo mineralization through mechanisms similar to neointimal calcification, resulting in the lethal disorder calcific aortic stenosis. valve calcification is almost entirely limited to the downstream (aortic) face of the leaflets. Formerly attributed to wear-and-tear injury, nonrheumatic calcific aortic valvular stenosis is now known to share clinical risk factors with athero sclerosis. 17 Chondro-osseous metaplasia is a common feature. 18 oxidant stress, 19 lipids, 20, 21 and Wnt-β-catenin-lrP-5 signaling 22, 23 have been implicated.
Etiology
vascular calcification is the culmination of several distinct, but often overlapping, pathological processes, such as chronic kidney disease, which Towler aptly named the "perfect storm" for vascular calcification. 24 These processes largely follow developmental programs that recapitulate embryonic ossification, with modulation by inflammatory or metabolic phenomena. These developmental programs play out in vascular cells exhibiting lineage plasticity and inflammatory responses to chronic oxidative stress.
Given the potential adverse consequences of uncontrolled biomineralization, calcium-phosphate metabolism is tightly regulated and mineralization ordinarily limited to skeletal bone by circulating and local inhibitors. vascular calcification was previously considered to be a purely degenerative, passive process, without biological regulation. Certain aspects of both skeletal and vascular calcification, such as extra cellular formation of calcium phosphate crystals, might be considered 'passive' because they are self-organized. In other respects, the process might be considered passive in that, when inhibitors are absent, such as in the matrix Gla protein (MGP)- deficient mouse, 25 then unopposed activators, such as bone morpho genetic protein (BMP) 2, drive osteogenic differentiation, giving the appearance of a spontaneous process. The current view, however, is that vascular calcifi cation is a biologically regulated process that-like osteogenesis-involves both activators and inhibitors.
Recapitulation of osteogenesis one of the first, and most compelling, clues that all types of vascular calcification may recapitulate chondroosteogenic processes was the presence of bone-like tissue ReviewS in atherosclerotic arteries and valves.
14,26 Indeed, 10-20% of atherosclerotic human vessels and valves contain architecturally complete, trabecular bone. 26 All stages of endochondral ossification are found in a careful survey of such lesions, 27 even fully formed marrow cavities with hematopoietic cells, vascular sinusoids, marrow adipocytes, and marrow stromal cells. 13, 27, 28 Spontaneous bone formation inside the wall of adult arteries is difficult to explain without new concepts, such as vascular stem cells. even amorphous calcification might be produced through recapitulation of some elements of osteochondrogenesis at the molecular and cellular levels. 29 Indeed, the amorphous calcified matrix might serve as a scaffold for fully modeled bone, just as calcified cartilage matrix serves as a scaffold for true endochondral bone formation in the growth plates of the skeleton. vascular calcium deposits can resemble bone from the macroscale to the nanoscale levels. Cellular components may include osteoblasts, osteoclasts, chondroblasts, chondroclasts, osteocytes, pericytes, lymphocytes, and vascular cells (Figure 2 ). The chondro-osseous mineral deposits contain 'osteoid' (bone matrix), which consists primarily of type I collagen, but also has noncollagenous bone matrix proteins, including osteopontin, bone sialoprotein, osteocalcin, fetuin A, and MGP. The nonmineral components of the deposits include cells, proteins, proteoglycans, 30 and lipids. 31 Interrogation of the mineral content in vascular lesions and cell cultures by energy dispersive X-ray analysis consistently yields a calciumphosphate molar ratio of approximately 1.6, matching that of hydroxyapatite (bone) mineral. 32, 33 Solid-state nuclear magnetic resonance spectroscopy of calcified plaques reveals molecular surface features matching those of bone. 30 Cellular plasticity and vascular stem cells ectopic bone in the artery wall is dramatic evidence of mesenchymal cell plasticity. The notion that smooth muscle cells undergo "de-differentiation into a synthetic phenotype" and "phenotypic modulation" has already gained acceptance, 34 and these terms may be viewed as euphemistic allusions to 'transdifferentiation' . Indeed, conventional distinctions among many cell lineages are becoming less clear as investigators report that endothelial cells differentiate to smooth muscle cells, 35 adult mesoangioblasts to myocytes and cardiomyocytes, 36 adipo cytes to vascular cells, 37 osteoclasts to dendritic cells, 38 dendritic cells to osteoclasts, 39 smooth muscle cells to osteoblasts, 40, 41 as well as microvascular pericytes to osteoblasts, myocytes and adipocytes. 42, 43 The doctrines of lineage commitment and terminal differentiation are giving way to the view of mesenchymal cell plasticity.
Theoretically, mature vascular cells, such as smooth muscle cells and valvular interstitial cells, might trans differentiate, or might dedifferentiate and then re differentiate, into osteochondrogenic cells. 40 The distinction-if there really is one-between such 'bornagain' osteo chondrogenic cells and vascular-stem-cellderived osteochondrocytic cells is unclear. As with other cells, vascular-cell differentiation responds to microenvironmental and mechanical cues. 44 As evidence of mechanical influence, mineral deposits co-localize with sites of mechanical stress on valves. 45 Furthermore, stiff substrates, such as fibronectin, induce osteochondrogenic differentiation, whereas distensible substrates, such as laminin, promote smooth muscle and/or adipogenic differentiation. 46 Since cross linking increases matrix stiffness, this process may account for the vascular cell ReviewS calcification induced by the matrix crosslinker transglutaminase 2. 47 Positive feedback may occur when calcium deposition increases plaque stiffness, which would induce osteochondrogenic differentiation of adjoining cells.
Adult mesenchymal stem cells residing in the artery wall have a lineage repertoire similar to that of marrow stromal cells. 36, 41, 43 located primarily in the subendothelial (perivascular) basement membrane, 37 they seem to form an anatomic continuum 48 ranging from the microvascular pericytes to the macrovascular intimal cells (previously known as 'atherophils' and 'intimacytes'). even the adventitial layer has subendothelial pericytes in its microvessels (that is, in the vasa vasorum). 49, 50 Calcification paradox Interestingly, radiological aortic calcification is often greater in patients with osteoporosis, independently of age, than in individuals without this condition. 51, 52 Public health programs currently promote calcium supplements to prevent osteoporosis, giving the impression that dietary calcium is the limiting factor for bone growth. How ever, the fact that the vascular tissues of patients with osteoporosis can produce mature, mineralized bone tissue raises questions about the need for dietary supplements and emphasizes the role of local, tissue-specific factors, such as inflammation, in osteoporosis.
If the relationship between vascular calcification and osteoporosis is independent of age, possible explanations for the correlation are that vascular calcification might cause osteoporosis, osteoporosis might cause vascular calcification, or the two processes share a common etiology. A potential shared etiologic factor is oxidant stress associated with hyperlipidemia. Although most-widely recognized in the vessel wall, hyperlipidemia also leads to deposition and nonenzymatic oxidation of lipoprotein particles in tissue. The proinflammatory lipid oxidation products initiate atherogenesis. They also accumulate in other tissues, including bone. 53, 54 This concept has led to the "lipid hypothesis of osteoporosis". 55 Mice fed high-fat diets develop skeletal bone loss, 56 which is accelerated in a setting of hyperlipidemia. 57 lipid oxidation products have direct effects on both bone-forming and bone-resorbing cells. They directly inhibit differentiation of osteoblasts 55 whilst directly inducing differentiation of osteoclasts. 58 They also regulate osteoclastogenic cytokines produced by osteoblasts 59 and T lymphocytes. 60 Studies have shown that inter mittent parathyroid hormone treatment for osteoporosis may not achieve efficacy in patients with hyperlipidemia because the oxidized lipids blunt the anabolic effects of para thyroid hormone in bone. 61, 62 Mechanisms of initiation Whereas intracellular osteogenic phenomena are being elucidated, the extracellular crystal initiation mechanism(s) remains less clear. In general, biomineralization is restricted to tissues that express both type I collagen and alkaline phosphatase; engineered coexpression of these proteins suffices to induce ectopic calcification. 63 Both type I collagen and alkaline phosphatase co-localize with mineral deposits in calcific atherosclerosis, 64 and are produced by vascular cells in vitro. 65, 66 Type I collagen, but not alkaline phosphatase, is present in normal artery wall. In mature osteoid, mineral is associated with fibrillar type I collagen. In early stages, crystallization may originate within extracellular membrane vesicles, such as matrix vesicles or apoptotic bodies, which offer a micro environment high in calcium and phosphate and carry membranebound alkaline phosphatase. 67 As observed by electron microscopy, such crystalline matrix vesicles are often in close proximity to apoptotic cells within athero sclerotic plaques, 68 and, when isolated, retain the ability to concentrate calcium and phosphate and initiate new crystal formation. 69, 70 Matrix vesicles might be specialized forms of general-purpose membrane vesicles used for intercellular communication, 71 whereas apoptotic bodies may represent a patho physiological surrogate. 72 Not all vascular calcification, however, may conform to this pathway, since passive processes accelerated by loss of inhibitors might also exist. In addition, medial calcification is often associated with elastin rather than type I collagen. 73, 74 elastin is a major component of the vascular wall and is present in atherosclerotic plaques. 75, 76 early crystal initiation might be supported by elastin fibers or their degradation products. 75, 76 Thus, although still associated with chondro-osseous conversion of vascular cells and the expression of regulatory proteins such as osteopontin, 77 vascular elastin calcification might involve unique regulatory pathways not present in normal bone.
Pyrophosphate, a water softener and a cause of pseudogout, potently inhibits calcium-phosphate crystal formation. Although alkaline phosphatase produces in organic phosphate, its main role in calcification is the breakdown of pyrophosphate. extracellular pyro phosphate is produced in the extracellular space from nucleotide triphosphates, such as ATP, by enzymes such as nucleotide pyrophosphatase 1. Pyrophosphate produced inside cells is exported via the trans membrane protein Ank. Deficiency of either nucleotide pyro phosphatase 1 or Ank in mice results in vascular and joint calcification with spontaneous chondrogenic metaplasia. 78 Human genetic disorders A lethal congenital disorder that causes myocardial infarction in infants is now recognized as homo zygous deficiency of the enzyme nucleotide pyro phosphatase 1, which results in pyrophosphate deficiency, and has been renamed generalized arterial calcification of in fancy. 79 Patients with another hereditary human disorder, fibrodysplasia ossificans progressiva, develop ectopic bone at sites of muscle and soft-tissue injury, gradually causing petrification of its victims. 80 The ectopic bone formation is mediated by cells of vascular origin, 81 which are derived from a lineage expressing Tie2 but not smooth-muscle myosin heavy chain, suggesting an endothelial or more-primitive pro genitor stem-cell origin. Patients with homozygous familial hyper cholesterolemia have pre mature severe calcific aortopathy and valvulopathy, suggesting a role for hyperlipidemia in both conditions. 82 
Regulatory factors
Factors that regulate vascular calcification are shown in Figure 3 . Developmental, inflammatory and metabolic factors all impact on this process.
Developmental factors
Several developmental regulatory factors, and their respective inhibitors, govern osteogenesis in skeletal bone and in both neointimal and medial vascular calcification. 83 Master transcription factors, such as Msx2, runx2 (also known as Cbfa1), osterix, and Sox9, designate cells for osteoblast, as opposed to chondrocyte, lineages directly or indirectly through induction of downstream mediators such as type I collagen, alkaline phosphatase, osteopontin, tissue factor, and osteocalcin.
Bone morphogenetic proteins BMP2 and BMP4, potent osteogenic differentiation factors originally isolated from bovine bone, induce ectopic ossification in muscle tissue in vivo and mineraliza tion in smooth muscle cells in vitro. BMP2 acts through runx2, 84 which induces expression of type I collagen and alkaline phosphatase. BMP2 is antago nized by noggin, chordin and MGP. 85 BMP4 is induced by tumor necrosis factor ligand superfamily member 11 (also known as receptor activator of nuclear factor kappa-B ligand or rANKl) in rat smooth muscle cells. 86 Another related protein, BMP7, inhibits calcification. 87 Matrix Gla protein MGP, a BMP inhibitor, associates with conventional (Framingham) cardiovascular risk factors, but, surprisingly, not with radiological coronary calcification. 88 MGP is more-highly expressed in calcified than in normal human arteries. 64 The inhibitory role of this protein in vascular calcification was revealed with the unexpected phenotype of the MGP-deficient mouse-complete ossification of the aortic wall and major branches by calcified cartilage. 25 later studies showed two mechanisms of MGP inhibition of calcification: direct binding of nascent crystals, and direct binding and inhibition of BMP2.
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MGP is inhibited, in turn, by heat shock protein 70, 90 as well as lack of vitamin K.
91 MGP function depends on vitamin-K-dependent gamma-carboxylation of glutamate residues, 91 a process inhibited by warfarin. Accordingly, long-term warfarin therapy is associated with increased femoral artery calcification, 1 and its possible contribution to other types of vascular calcification is under investigation. RANKL expressed by osteoblasts, rANKl is an essential regulator of osteoclast differentiation. Deficiency of osteoprotegerin, a decoy receptor for rANKl, leads to medial calcification 92,93 and acceleration of atherosclerosis in hyperlipidemic mice. 91 Unexpectedly, rANKl levels increase with age and reliably predict cardiovascular events. 94 The osteoprotegerin-rANKl system may govern differentiation of osteoclast-like cells at sites of vascular calcification. 26, 95 inflammatory factors Inflammation is closely associated with calcification. Macrophages, lymphocytes, and dendritic cells infiltrate plaque and release cytokines that regulate calcification. 38, 58 Perivascular adipose inflammation, 96,97 and systemic inflammation associated with chronic kidney disease, 98 might also contribute to both neointimal and medial calcification. A primary link between inflammatory and developmental mechanisms was identified as the tumor necrosis factor (TNF) activation of the Msx2-Wnt-β-catenin signaling cascade, an upstream pro-osteogenic pathway in osteoblast precursors of intramembranous bone that is also activated in the vessels of diabetic, hyperlipidemic mice.
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Tumor necrosis factor TNF induces the Msx2-Wnt-beta-catenin signaling pathway, 99 as do oxidant stress 5 and hyperphosphatemia. 100 TNF also promotes calcification in vitro by reducing expression of antiapoptotic Gas6, 101 and by inducing alkaline phosphatase activity via protein kinase A signaling. 66 TNF may also act on alkaline phosphatase via NADPH-mediated generation of reactive oxygen species and induction of Msx2 expression. 5, 102 In vivo, targeted TNF overexpression in smooth muscle cells enhances Msx2-Wnt-induced calcification in lDl-receptor-knockout mice, and the clinically used mono clonal antibody to TNF, infliximab, inhibits Wnt activation and calcification in these mice. 107 and adiponectin. 101 The role of Gas6 and Axl in cardiovascular diseases might be complex, since they also mediate atherogenesis, platelet function and immune cell activation.

Gas6 and Axl
Fetuin A Fetuin A, an abundant serum protein produced in the liver, binds and complexes calcium phosphate nanocrystals, to form calcioprotein particles and thereby prevents aggregation of calcium phosphate into insoluble mineral crystals and further growth. Fetuin A also promotes cellular uptake and removal of the complexes. 108 As seen in bone, fetuin A accumulates at sites of vascular calcification. 109 other bone-associated proteins, including osteopontin, also bind calcium phosphate crystals. 110 In vitro, fetuin A taken up by vascular smooth muscle cells reduces the ability of their matrix vesicles to calcify. 109, 111 low fetuin-A levels are associated with increased vascular calcification and mortality in patients with chronic kidney disease. 112 Crystals Nanoscale hydroxyapatite crystals might have direct biological effects on cells through physicochemical interactions that trigger inflammation and apop tosis. 30, 33 These effects are known for pyrophosphate and urate crystals, but less appreciated for hydroxyapatite. 113 A positive feedback loop may ensue when inflammation triggers mineralization and mineralization triggers inflammation. In osteoarthritis, crystals induce synthesis and secretion of matrix metalloproteinases and cell proliferation through erK and calcium signaling. 114 Metabolic factors excess lipids, phosphate and/or glucose, in the setting of chronic diseases, have direct and indirect effects on vascular calcification. oxidant stress might be a central downstream mediator of these changes and their link with inflammatory and developmental processes described above.
Oxidant stress oxidant stress, alone, promotes vascular-cell cal cification, 115 and may account for the procalcific effects of inflammatory cytokines, oxidized lipids, and certain oxysterols. The classical oxidant stressor, H 2 0 2 , promotes osteochondrocytic differentiation of vascular smooth muscle cells by upregulating runx2. 65 The level of reactive oxygen species is increased at sites of calcification in human valves. 19, 116 Products of lipid oxidation, such as minimally-modified lDl and oxidized phospholipids, induce osteogenic, 55, 117 and apoptosis-mediated, 118 calcifi cation of vascular cells. The osteogenic differentiation induced by TNF and H 2 0 2 is inhibited by insulin-like growth factor 1.
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Hyperphosphatemia
The important role of hyperphosphatemia in the medial calcification associated with chronic kidney disease has been reviewed in detail elsewhere. 73, 100 Briefly, hyperphosphatemia, in addition to chemically promoting crystal formation, is sufficient in vitro to increase osteochondrogenic gene expression in smooth muscle cells. 120, 121 Serum phosphate levels are regulated by phosphate itself, parathyroid hormone, and vitamin D, 122 as well as by fibroblast growth factor 23, which is released from bone osteocytes and activates its co-receptor Klotho in the kidney, to control phosphate elimination. 123 Vitamin D High-dose dietary vitamin D reliably induces medial calcifi cation; it is often used to generate vascular calcification in animal models. 124 Although vitamin D generated in the skin by ultraviolet light is carried in the circulation by vitamin-D-binding protein, dietary vitamin D is carried into the circulation via chylo microns and then lipo protein particles. When lipoprotein particles deposit in atherosclerotic plaque, the vitamin D they carry might be converted to the active form by the 1-alpha-hydroxylase expressed in vascular smooth muscle cells and in monocytes and macrophages. This possibility raises interesting questions about the potential for vitamin D to promote atherosclerotic calcification and cardio vascular risk. epidemiologically, both excess and insufficient vitamin D are associated with increased cardiovascular risk. 125 Insulin and glucose Studies in cultured smooth muscle cells have demonstrated that glucose directly promotes vascular cell calcification, and insulin inhibits it. 126, 127 Despite the recognized increase in calcification observed in patients with diabetes, the role of glucose itself in humans remains to be determined.
Leptin and adiponectin
The adipose-derived factors leptin and adiponectin promote and inhibit vascular calcification, respectively. [128] [129] [130] Initially implicated in vitro, 129 ,101 the potentially important and direct roles of these metabolic hormones were recently validated by the report of increased vascular calcification in leptin-treated, 130 and adiponectin-knockout, 128 mice.
Treatments
Currently, no therapy is available to reverse vascular calcification; several are available for underlying disorders such as atherosclerosis, chronic kidney disease, diabetes mellitus, and osteoporosis. Interestingly, in chronic kidney disease, new therapies are largely judged by their impact on vascular (medial) calcification. 131 Under investi gation are HMG-CoA reductase inhibitors (statins), sevelamer, bisphosphonates, the phosphate binder lanthanum carbo nate, alkaline phosphatase inhibi tors, calcimimetics, and the rANKl blocker denosumab. Despite their potential, cholesterol-lowering statins have not been shown effective in preventing or reversing vascular calcification. Importantly, pro calcific treatments used for skeletal osteoporosis may have adverse effects on vascular calcification.
Conclusions vascular mineral deposition results from several different pathways involving metabolic and/or inflammatory processes that trigger reversion to embryonic developmental programs for osteochondrogenesis. What evolu tionary advantage might this confer? one possibility is that softtissue calcification in general is an immune response of last resort. Certain chronic infections, such as mycobacteria, parasitic worms, abscesses, or foreign body infections, can be unabated by cellular and humoral immunity. By surrounding such infections with a wall of bone, the body might contain the noxious focus. radiologists have described such calcified structures as 'ostrich eggs' . The capacity of the artery wall to generate complete, vascularized, trabecular bone tissue, as well as cartilage and fat, should capture the attention of investigators in tissue regenerative and tissue engineering medicine.
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